TriSalus Life Sciences (TLSI) to Announce Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1550) per share and revenue of $10.2670 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $4.38 on Thursday. The company has a market capitalization of $269.02 million, a PE ratio of -3.11 and a beta of 0.43. The firm has a fifty day simple moving average of $3.96 and a 200-day simple moving average of $4.35. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TLSI shares. Lake Street Capital cut their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings downgraded TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 39,682 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $2.59 per share, for a total transaction of $102,776.38. Following the purchase, the chief executive officer owned 1,065,215 shares in the company, valued at $2,758,906.85. This represents a 3.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael P. Stansky bought 410,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $2.50 per share, with a total value of $1,025,000.00. Following the completion of the purchase, the director owned 1,240,722 shares in the company, valued at approximately $3,101,805. The trade was a 49.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 719,682 shares of company stock valued at $1,804,176 in the last three months. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TLSI. Invesco Ltd. acquired a new position in TriSalus Life Sciences during the 4th quarter worth $72,000. Man Group plc acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter valued at about $102,000. Abel Hall LLC bought a new position in shares of TriSalus Life Sciences during the fourth quarter worth about $73,000. Kotler Kevin bought a new position in shares of TriSalus Life Sciences during the fourth quarter worth about $1,013,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in TriSalus Life Sciences in the fourth quarter worth about $104,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.